Unlocking the Future of Cell Screening with Groundbreaking Innovation
MicroOmix is a pioneering startup powered by patented technology from the CNRS and the University of Strasbourg, setting a new standard in high-throughput cell screening. Our cutting-edge platform analyzes cells based on the molecules they secrete, with a level of precision and resolution that is unrivaled.
Secreted molecules are at the heart of critical biological processes—driving immune responses, cell migration, tissue regeneration, and differentiation. Emerging research reveals their pivotal role in disease progression and therapeutic effectiveness, but until now, accessing these insights has been beyond reach.
MicroOmix is changing that. Our advanced droplet-based assays, seamlessly integrated with any droplet microfluidics system, empower researchers and biopharma innovators to:
- Uncover previously undetectable key cells, molecules, and biological mechanisms.
- Precisely profile, isolate, and purify delicate cellular subpopulations with unparalleled accuracy.
We are on a mission to transform the development of next-generation biotherapies, cell therapies, and diagnostics for the most complex diseases—cancer, autoimmune disorders, neurodegenerative diseases, and beyond.
Join us as we push the boundaries of what's possible in medical innovation.
Company Details
- Employees
- 5
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://microomixtech.com/
Microomix Questions
Microomix's website is https://microomixtech.com/
Microomix's LinkedIn profile is https://www.linkedin.com/company/microomix
Microomix has
5 employees.
View email and phone details for 5
employees at Microomix.
Microomix's industry is
Biotechnology Research
Microomix's top competitors are
Lianeli,
Lactips,
Lamina Therapeutics,
Hyloris Pharmaceuticals,
Livedrop Bio,
Pdc*line Pharma,
2am Software,
Clhynn,
Microomics Systems S.l.,
Amyl Therapeutics.
Microomix's categories are Biotechnology Research
